IP Library › Granted Patent US 8,137,667
Granted Patent B2
US 8,137,667 · App. 12/653,137 · Granted Mar 20, 2012

Fully human antibodies against human 4-1BB

Assignee: Bristol-Myers Squibb Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,137,667
App. No.
12/653,137
Granted
Mar 20, 2012
Kind
B2
Abstract

Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Claims (7)

1. A method for treating a cancer in a subject comprising administering a therapeutically effective amount of a monoclonal antibody or antigen-binding portion thereof that specifically binds to 4-1BB to said subject, said monoclonal antibody or antigen-binding portion thereof comprising a light chain variable region and a heavy chain variable region, wherein:

said light chain variable region comprises a CDR1 having amino acids 44-54 of SEQ ID NO:6, a CDR2 having amino acids 70-76 of SEQ ID NO:6, and a CDR3 having amino acids 109-119 of SEQ ID NO:6; and

said heavy chain variable region comprises a CDR1 having amino acids 50-54 of SEQ ID NO:3, a CDR2 having amino acids 69-84 of SEQ ID NO:3, and a CDR3 having amino acids 117-129 of SEQ ID NO:3.

2. The method of claim 1 wherein:

said light chain comprises a variable region having amino acids 21-129 of SEQ ID NO:6; and

said heavy chain comprises a variable region having amino acids 20-140 of SEQ ID NO:3.

3. The method of claim 1 wherein said light chain comprises amino acid residues 21-236 of SEQ ID NO:6 and said heavy chain comprises amino acid residues 20-467 of SEQ ID NO:3.

Continuity (2)
Continuation 11903106 · Sep 20, 2007
Related Publication 20100183621A1 · Jul 22, 2010